This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

ThromboEmbolism Prevention Efficacy and Safety Trial (TEMPEST) (TEMPEST)

This study has been completed.
Information provided by (Responsible Party):
GlaxoSmithKline Identifier:
First received: July 9, 2002
Last updated: May 24, 2017
Last verified: May 2017
The purpose of this study is to gain additional safety information as well as to determine after the study drug has been given to patients who have undergone total hip replacement surgery, whether the study drug is effective in preventing late deep vein thrombosis (blood clots in legs) or pulmonary embolism (blood clots in lungs).

Condition Intervention Phase
Arthroplasty Drug: SB-424323 Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: ThromboEMbolism Prevention Efficacy and Safety Trial (TEMPEST): A Double-blind Four-week Study to Assess the Efficacy, Safety, and Tolerability of SB-424323 in the Extended Prophylaxis of Patients Following Total Hip Arthroplasty

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • VTE [ Time Frame: 28 day treatment period ]
    Incidence of VTE during the 28-day treatment period, including death due to VTE

Secondary Outcome Measures:
  • types of VTE [ Time Frame: 28 day treatment period ]
    The incidence of the types of VTE including, DVT (deep vein thrombosis), symptomatic VTE, PE] and anti-IIa activity

Enrollment: 343
Study Start Date: January 2002
Study Completion Date: May 2003
Primary Completion Date: May 2003 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SB424323, 500 mg BID Drug: SB-424323
500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
Experimental: SB424323, 125 mg BID Drug: SB-424323
500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
Placebo Comparator: Placebo Drug: Placebo
matching placebo, oral, BID for 28 days


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients scheduled for primary elective unilateral total hip arthroplasty (i.e. first time the hip is being replaced on the operative side).
  • Patients who have given written informed consent to participate in this study.

Exclusion Criteria:

  • Patients with a contraindication to contrast venography
  • Patients with an increased risk of bleeding.
  • Patients with a predefined risk for prethrombotic episodes or a history of thrombophilia.
  • Other inclusion or exclusion criteria to be determined by the physician and study sponsor.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00041509

Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Responsible Party: GlaxoSmithKline Identifier: NCT00041509     History of Changes
Other Study ID Numbers: 424323/025
Study First Received: July 9, 2002
Last Updated: May 24, 2017

Keywords provided by GlaxoSmithKline:
venous thromboembolism
pulmonary embolism
deep vein thrombosis

Additional relevant MeSH terms:
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases processed this record on August 18, 2017